Uveal Melanoma
Conditions
Keywords
Crizotinib, 14-063
Brief summary
The study is designed to determine the 32 month rate of distant relapse in patients with uveal melanoma who are at high risk of recurrence following definitive therapy with surgery or radiation who receive adjuvant crizotinib; and secondarily, the overall survival and disease specific survival in this patient population.
Detailed description
Uveal melanoma is the most common primary intraocular malignancy in adults, and arises from melanocytes within the choroid plexus of the eye. Melanomas of the ocular and adnexal structures comprise approximately 5% of all melanomas and are biologically and prognostically distinct from cutaneous melanoma. In the United States, an estimated 2000 patients are diagnosed with this disease each year. The development of metastasis in this disease is common and occurs in approximately 50% of patients with posterior uveal melanoma within 15 years after the initial diagnosis and treatment. Uveal melanoma is thought to be particularly resistant to systemic treatment, and no systemic therapy has yet been demonstrated to improve survival. Drugs commonly used to treat advanced cutaneous melanoma rarely achieve durable responses in patients with uveal melanoma.
Interventions
DRUGCrizotinib
An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK. Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration.
Sponsors
Pfizer
Columbia University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Primary diagnosis of uveal melanoma at least 12 mm in largest basal diameter as clinically determined by the treating investigator. Cytologic determination of diagnosis is not required. Size is based on clinical assessment (e.g. by ultrasound or direct ophthalmoscopy) prior to enucleation or radiation therapy. * Definitive therapy of the primary uveal melanoma must have been performed within 90 days of initiating protocol therapy. * High-risk (class 2) uveal melanoma as determined by gene expression profiling * No evidence of metastatic disease. * Age ≥18 years. * Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥ 70%. * Life expectancy of greater than 3 months. * Able to swallow and retain orally-administered medication and does not have any clinically significant gastrointestinal abnormalities that may alter absorption such as malabsorption syndrome or major resection of the stomach or bowels * Patients must have normal organ and marrow function as defined below: * Absolute neutrophil count (ANC) \>1,000 cells/mm³ * Platelet count \>75,000/mm³ * Hemoglobin \>9.0g/dL * Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) \<3x upper limited of normal (ULN) * Total bilirubin \<2x ULN * Alkaline phosphatase \<3x ULN * Serum creatinine \<2x ULN or a creatinine clearance \> 60mL/min * Note: Patients with hyperbilirubinemia clinically consistent with an inherited disorder of bilirubin metabolism (e.g., Gilbert syndrome) will be eligible at the discretion of the treating physician and/or the principal investigator. * Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation until 4 months after completion of crizotinib administration. Women of child-bearing potential must have a negative serum pregnancy test within 14 days prior to study entry. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study therapy, and 4 months after completion of crizotinib administration. * Ability to understand and the willingness to sign a written informed consent document.
Exclusion criteria
* History of another malignancy except for those who have been disease-free for 3 years, or patients with a history of completely resected non-melanoma skin cancer and/or patients with indolent secondary malignancies not requiring active therapy, are eligible. Consult the study Principal Investigator if unsure whether second malignancies meet the requirements specified above. * Any major surgery or extensive radiotherapy (except that which is required for definitive treatment of primary uveal melanoma), chemotherapy with delayed toxicity, biologic therapy, or immunotherapy within 21 days prior to initiation of study therapy. * History of prior crizotinib use. * Use of other investigational drugs within 28 days (or five half-lives, whichever is shorter; with a minimum of 14 days from the last dose) preceding the first dose of study therapy and during the study. * Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to crizotinib. * Concurrent administration of crizotinib and a strong inhibitor or inducer of CYP3A is not permitted. Many over-the-counter and dietary supplements also inhibit or induce CYP3A and thus are prohibited. * A QT interval corrected for heart rate using the Bazett's formula QTcB ≥ 480 msec. * Concurrent administration of crizotinib and agents that can cause QTc prolongation is not permitted. * Known Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV) infection (with the exception of chronic or cleared HBV and HCV infection, which will be allowed). HIV-positive patients on combination antiretroviral therapy are ineligible because of the potential for pharmacokinetic interactions with crizotinib. In addition, these patients are at increased risk of lethal infections when treated with marrow-suppressive therapy. * Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Relapse Free Survival (RFS) Rate at 32 Months | 32 Months | RFS rate will be defined as the percentage of patients who do not experience any new tumor growth at any site on the body distant from the primary site or death from any cause from the time of study entry to the end of the relevant timepoint. RFS probabilities were estimated using Kaplan-Meier method. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) | Up to 36 months | OS will be defined as the time from treatment start to date of death or last followup. Participants were followed up to 36 months after treatment start and Kaplan-Meier survival analysis was used to generate the Overall Survival estimate. |
| Disease-Specific Survival (DSS) Time | Up to 36 months | DSS is defined as the time from treatment start to death due to disease or last followup. Participants who die from other causes will be censored. |
| Number of Participants With Treatment Discontinuation Due to Toxicity | 48 weeks | Toxicity grading will be performed in accordance with NCI CTCAE, version 4.0. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Crizotinib Subjects will receive 48 weeks (12 four-week cycles) of crizotinib 250 mg PO twice a day (BID). Subjects will be evaluated by routine bloodwork and physical exam every 4 weeks while they are receiving crizotinib and during follow up period.
Crizotinib: An anti-cancer drug acting as an anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.
Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration. | 34 |
| Total | 34 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Lost to Follow-up | 2 |
Baseline characteristics
| Characteristic | Crizotinib |
|---|---|
| Age, Continuous | 60 years |
| Eastern Cooperative Oncology Group (ECOG) Status | 0 units on a scale |
| Largest basal diameter | 14.0 mm |
| Race/Ethnicity, Customized Hispanic | 2 Participants |
| Race/Ethnicity, Customized Other/Unknown | 7 Participants |
| Race/Ethnicity, Customized White | 25 Participants |
| Region of Enrollment United States | 34 participants |
| Sex: Female, Male Female | 14 Participants |
| Sex: Female, Male Male | 20 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 11 / 34 |
| other Total, other adverse events | 34 / 34 |
| serious Total, serious adverse events | 3 / 34 |
Outcome results
Primary
Relapse Free Survival (RFS) Rate at 32 Months
RFS rate will be defined as the percentage of patients who do not experience any new tumor growth at any site on the body distant from the primary site or death from any cause from the time of study entry to the end of the relevant timepoint. RFS probabilities were estimated using Kaplan-Meier method.
Time frame: 32 Months
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Crizotinib | Relapse Free Survival (RFS) Rate at 32 Months | 50 Probability |
Secondary
Disease-Specific Survival (DSS) Time
DSS is defined as the time from treatment start to death due to disease or last followup. Participants who die from other causes will be censored.
Time frame: Up to 36 months
Population: Data needed for for DSS calculation (death due to disease) was not collected as participants were no longer actively followed at the time of death.
Secondary
Number of Participants With Treatment Discontinuation Due to Toxicity
Toxicity grading will be performed in accordance with NCI CTCAE, version 4.0.
Time frame: 48 weeks
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Crizotinib | Number of Participants With Treatment Discontinuation Due to Toxicity | 4 Participants |
Secondary
Overall Survival (OS)
OS will be defined as the time from treatment start to date of death or last followup. Participants were followed up to 36 months after treatment start and Kaplan-Meier survival analysis was used to generate the Overall Survival estimate.
Time frame: Up to 36 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Crizotinib | Overall Survival (OS) | 68.3 months |